<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622230</url>
  </required_header>
  <id_info>
    <org_study_id>XinjiangUP-WY-201501</org_study_id>
    <nct_id>NCT02622230</nct_id>
  </id_info>
  <brief_title>Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics of Mianhuahua Flavonoids Tablets After Oral Administration In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinjiang Uygur Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinjiang Uygur Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability, and to evaluate the
      pharmacokinetic characteristics of Mianhuahua Flavonoids Tablets after oral administration in
      healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Dose-escalation study of single oral administration of Mianhuahua Flavonoids Tablets in
           healthy adults to assess the safety and tolerability.

        2. Multiple-dose study of Mianhuahua Flavonoids Tablets in healthy adults to assess the
           safety and tolerability.

        3. Dose-escalation study of single oral administration of Mianhuahua Flavonoids Tablets in
           healthy adults to evaluate the pharmacokinetic characteristics

        4. Multiple-dose study of Mianhuahua Flavonoids Tablets in healthy adults to evaluate the
           pharmacokinetics characteristics
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeated oral administration of Mianhuahua Flavonoids Tablets as measured by the frequency of drug-related clinical adverse events in healthy adults.</measure>
    <time_frame>Period I: single dose,up to 7 Days;Period II: repeated dose,up to 36 Days</time_frame>
    <description>Safety and tolerability will be evaluated through Composite Metrics：adverse events, vital signs, electrocardiograms, physical exams, and clinical laboratory assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under curve(AUC) of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cls of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css_max of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css_min of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tss_max of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under curve of steady state(AUCss) of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of fluctuation（DF） of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.</measure>
    <time_frame>up to 29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mianhuahua Flavonoids Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mianhuahua Flavonoids Tablets, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mianhuahua Flavonoids Tablets</intervention_name>
    <description>Tolerability Study:
Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)
Pharmacokinetic Study:
Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)</description>
    <arm_group_label>Mianhuahua Flavonoids Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match with experimental groups</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, between 18 and 45 years of age, Body Mass Index (BMI) between 19～24
             kg/m2, Weight &gt; or = 50kg

          -  In good health as judged by the investigator

          -  Agreed to take effective contraceptive measures during the test and within 6 months
             after the last drug administration

          -  Signed informed consent form and fully understood the contents, process and possible
             adverse reactions of the test

        Exclusion Criteria:

          -  Pregnancy and lactation

          -  History of kinds of food or drug allergy, or suffering from allergic diseases or
             allergic constitution

          -  Presence (in screening stage) or history of the acute/chronic organic diseases or
             clinical manifestations: Including but not limited to blood system, renal disease,
             liver disease, endocrine system, respiratory system, digestive system, cardiovascular
             system, nervous system, mental disease, or any disease and physiological conditions
             interfering with the results of the test

          -  with a clinically significant abnormality in routine serological detection: including
             Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus
             (HIV) infected

          -  History of abuse of drugs, or the result of drug abuse test is positive

          -  Alcohol intake more than 2 units (1 unit is equal to 12 ounces or 360 ml beer, 5
             ounces or 150 ml liquor, 1.5 ounces or 45 ml distilled spirits ) per day on average
             within 3 months before the test, or the result of alcohol test is positive

          -  Smoking more than 5 cigarettes per day, or using quite amount of nicotine products
             within 3 months before the test, or unable to stop smoking during the test

          -  Excessive consumption of xanthine soda drinks, more than four cups or bottles per day

          -  With major surgical operations and blood or blood component transfusion within 4 weeks
             before the test

          -  Severe blood loss or blood donation more than 400ml within 2 months before the test

          -  Participation in other drug trials within 3 months before the test

          -  Usage of any drugs within 2 weeks before the test, or within 5 times of drug
             eliminated half-life or pharmacodynamics half-life; Vaccination within 4 weeks before
             the test; Acceptance of biological agents within 4 months before the test

          -  Be otherwise unsuitable for the study, in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>QIU Fu rong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shuguang Hospital affiliated with Shanghai University of TCM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MU Dan dan</last_name>
    <phone>86-0991-3768609</phone>
    <email>mudandan@renfu.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>YIN Hai long</last_name>
    <phone>86-0991-3768609</phone>
    <email>yinhailong@renfu.com.cn</email>
  </overall_contact_backup>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uygur Medicine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

